• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5072719)   Today's Articles (33)
For: Shirley M. Relugolix: A Review in Advanced Prostate Cancer. Target Oncol 2023;18:295-302. [PMID: 36652173 DOI: 10.1007/s11523-022-00944-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/14/2022] [Indexed: 01/19/2023]
Number Cited by Other Article(s)
1
Navin AK, Rejani CT, Chandrasekaran B, Tyagi A. Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC). Biomed Pharmacother 2025;187:118058. [PMID: 40253830 DOI: 10.1016/j.biopha.2025.118058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 04/03/2025] [Accepted: 04/14/2025] [Indexed: 04/22/2025]  Open
2
De La Cerda J, Belkoff L, Courtney KD, Diamond E, D'Olimpio J, Dunshee C, Gervasi L, Goodman M, Mittal K, Morris D, Sieber P, Tutrone R, Ryan M, Zhong Y, Ufer M, Shore N. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial. Target Oncol 2025;20:503-517. [PMID: 40180682 DOI: 10.1007/s11523-025-01139-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/17/2025] [Indexed: 04/05/2025]
3
Coelingh Bennink HJT. New endocrine method of oral male contraception. Contraception 2025;145:110782. [PMID: 39674335 DOI: 10.1016/j.contraception.2024.110782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Revised: 12/04/2024] [Accepted: 12/07/2024] [Indexed: 12/16/2024]
4
Brimhall DB, Chen Y, Lee S, Yoshida K, Ufer M. Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women. Pharmacol Res Perspect 2025;13:e70067. [PMID: 39887952 PMCID: PMC11781947 DOI: 10.1002/prp2.70067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2024] [Revised: 12/13/2024] [Accepted: 01/10/2025] [Indexed: 02/01/2025]  Open
5
Jabbari P, Yazdanpanah O, Benjamin DJ, Rezazadeh Kalebasty A. The Role of Ayurveda in Prostate Cancer Management. Integr Cancer Ther 2025;24:15347354251330906. [PMID: 40156363 PMCID: PMC11954515 DOI: 10.1177/15347354251330906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2024] [Accepted: 03/13/2025] [Indexed: 04/01/2025]  Open
6
Li R, Chen X, Wang Y. Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS). PLoS One 2024;19:e0312481. [PMID: 39436909 PMCID: PMC11495556 DOI: 10.1371/journal.pone.0312481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2024] [Accepted: 10/07/2024] [Indexed: 10/25/2024]  Open
7
Reiss AB, Vasalani S, Albert J, Drewes W, Li K, Srivastava A, De Leon J, Katz AE. The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer. MEDICINA (KAUNAS, LITHUANIA) 2024;60:1727. [PMID: 39596912 PMCID: PMC11596556 DOI: 10.3390/medicina60111727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2024] [Revised: 10/09/2024] [Accepted: 10/17/2024] [Indexed: 11/29/2024]
8
Thomson A, Gunn L, Victor D, Adamson E, Thakrar K. Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report. Res Rep Urol 2024;16:245-252. [PMID: 39399307 PMCID: PMC11471072 DOI: 10.2147/rru.s485238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Accepted: 09/26/2024] [Indexed: 10/15/2024]  Open
9
Liu HN, Zhu Y, Chi Y, Sun FF, Shan LS, Wang YT, Dai B. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications. Eur J Med Chem 2024;276:116722. [PMID: 39079309 DOI: 10.1016/j.ejmech.2024.116722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2024] [Revised: 07/22/2024] [Accepted: 07/25/2024] [Indexed: 08/11/2024]
10
Modi D, Hussain MS, Ainampudi S, Prajapati BG. Long acting injectables for the treatment of prostate cancer. J Drug Deliv Sci Technol 2024;100:105996. [DOI: 10.1016/j.jddst.2024.105996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/05/2024]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA